Follow America's fastest-growing news aggregator, Spreely News, and stay informed. You can find all of our articles plus information from your favorite Conservative voices. 

The U.S. Supreme Court (SCOTUS) is set to make a major ruling on abortion ahead of the upcoming presidential election, in light of recent successes for abortion rights supporters.

Last Tuesday, Ohio saw a ballot measure victory, Kentucky’s Democratic governor was reelected on a pro-abortion platform, and the Pennsylvania Supreme Court seat was won by a Democrat who had pledged to uphold abortion rights.

This has resulted in attempts to introduce ballot measures in several swing states: Arizona, Florida, Nevada, and Pennsylvania.

Additionally, it has been revealed that powerful billionaires such as George Soros and Warren Buffett have sought to generate substantial profits from the controversial drug RU-486 through a shell corporation in the Cayman Islands. This pill was enabled through deals between the Rockefeller Foundation and President Bill Clinton’s Food and Drug Administration (FDA).

In response to this approval of mifepristone (also known as RU-486), an Alliance Defending Freedom representing various pro-life medical organizations sued the FDA last November.

Subsequently, a federal district court in Texas ruled against the FDA’s “unlawful approval” of mifepristone in April this year.

In September, the Justice Department and the manufacturer of mifepristone requested that the Supreme Court of the United States (SCOTUS) overturn a ruling by a lower court which limited access to mifepristone.

At present, SCOTUS has yet to decide on the drug’s final fate, though abortion proponents – including representatives from all 49 U.S. states – have asked the court to maintain availability and distribution of the drug through entities such as Planned Parenthood.

Shortly after President Clinton’s inauguration in January 1993, he signed multiple executive orders increasing access to abortion. One of these directives allowed the sale of RU-486 and other abortion-inducing drugs.

In April 1993, representatives from the Rockefeller Population Council and Hoechst began meeting with the FDA.

Reports indicated that some Hoechst officials were “dismayed” at accusations from pro-life groups comparing their actions to what the Nazis had done to Jews during WWII.

It should be noted that Hoechst was a successor of I.G. Farben, which manufactured cyanide gas for concentration camps and became known as “the devil’s chemist” due to its involvement in Hitler’s war machine.

In 2021, the Rockefeller Foundation distanced itself from its past involvement in eugenics, which was reported by The Jerusalem Post.

“The Rockefeller Foundation is currently reckoning with our own history in relation to eugenics,” stated foundation President Rajiv Shah. Following the Clinton administration’s approval of RU-486 in 1993, the Rockefeller Foundation’s Population Council licensed the patent rights to a group called Danco Laboratories.

This allowed them to form alliances with pro-abortion organizations such as National Abortion Federation, Planned Parenthood of America and National Abortion and Reproductive Rights Action League.

Drug-induced or chemical abortions now account for more than half of all abortions in the US, according to a study cited in one of the Texas court filings currently under review by the Supreme Court.

This study concluded that drug-induced abortions, such as those using mifepristone, came with an increased risk of adverse events compared to surgical abortions. Specifically, these risks included a fourfold higher chance of hemorrhaging, incomplete abortion and unplanned surgical evacuation.

Additionally, 77.1 percent of mifepristone patients reported post-abortion pain compared to 10.5 percent of surgical patients. The suit alleged this discrepancy. A decision from the Supreme Court is anticipated in the upcoming months.

ICYMI: Rep. Matt Gaetz Files Ethics Complaint Against Former House Speaker Kevin McCarthy For Assaulting Rep. Tim Burchett

1 comment

Your email address will not be published. Required fields are marked *